Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients

A series of Live Grand Rounds Programs, Chapter Meetings, and an on-demand CME-certified Webcourse.

Welcome to "Oncology Exchange: Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients." This CME-certified initiative is intended for community-based medical oncologists/hematologists and other clinicians involved in the care of patients with MCL. A series of live CME-certified programs will be presented at selected hospitals and ASCO State/Regional meetings throughout the US during 2014/2015, and an online CME-certified webcourse will be available in late 2014.

Program Description:

Newly approved agents, recently updated clinical practice guidelines, and emerging data from ongoing studies of novel treatment regimens in mantle cell lymphoma (MCL) have led to a dramatic change in the outlook for patients with the disease. However, this changing treatment paradigm in MCL poses several new challenges to community clinicians. This activity will provide guidance on the emerging and evidence-based frontline therapeutic options for elderly patients, recent drug approvals for relapsed/refractory patients with MCL, monitoring response to therapy, and the role of patient education to make optimal therapeutic choices and improve treatment adherence.

Accreditation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statements:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please email contact@rockpointe-pcme.com.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Chapter Meetings


Related Online Offerings

Back to Top

A calendar of live events, as well as additional CME/CE-certified online activities, for this and other Oncology Exchange programming, can be found at: http://www.medscape.org/sites/advances/oncologyexchange.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the Visiting Professor Series, "Oncology Exchange: Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Review diagnostic and prognostic considerations in MCL
  • Evaluate emerging and evidence-based frontline approaches for elderly patients with MCL
  • Review the current and emerging treatments in the relapsed/refractory setting for patients with MCL

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)

Steering Committee and Speaker Biographies

Back to Top

IZIDORE LOSSOS, MDIZIDORE LOSSOS, MD
Director, Lymphoma Program
Professor of Medicine
University of Miami
Sylvester Comprehensive Cancer Center
Miami, FL


Izidore Lossos, MD is a Professor of Medicine and Director of the Lymphoma Program at the University of Miami's Sylvester Comprehensive Cancer Center in Miami, FL. A recognized expert and leader in the field of lymphoma, Dr. Lossos' research expertise spans basic studies in lymphoma pathogenesis, studies on the role of microRNAs in lymphocyte biology, translational studies investigating prognostic biomarkers, preclinical evaluations of novel therapeutic approaches, and clinical studies of lymphoma treatments.

Dr. Lossos and his team were responsible for the establishment of the 6-gene and 2-gene models for prognosis prediction in diffuse large B-cell lymphoma (DLBCL), as well as the identification of specific microRNAs, including miR-181a, as independent predictors of survival in DLBCL. He also has a major interest in understanding the mechanisms of lymphoma pathogenesis, identification of aberrant signaling pathways, identification of novel genes that may have a unique role in this disease, and construction of molecular prognostic models that will allow identification of patients that will respond to therapy.

Dr. Lossos earned his medical doctorate from the Hadassah School of Medicine, Israel, Jerusalem, and completed his post-doctoral studies in lymphoma at Stanford University. Overall, Dr. Lossos and his laboratory are well funded and very active, with more than 60 publications in the last 5 years.


SONALI M. SMITH, MDSONALI M. SMITH, MD
Associate Professor, Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, IL


Sonali M. Smith, MD is an Associate Professor in the Department of Medicine at the University of Chicago, and the Director of the Lymphoma Program. She focuses on the care and treatment of adults with Hodgkin and non-Hodgkin lymphoma. She has a special interest in the development of new agents for lymphoma and in understanding the link between the environment and the prognosis and biology of lymphoma. In addition, she is working to improve the survival of patients with relapsed lymphomas through the use of stem-cell transplantation. She is Principal Investigator of a number of innovative trials, many of which incorporate the collection of tumor and blood samples. She works with collaborative laboratories to study the effects of treatment on cancer cells.

Dr. Smith serves on multiple national committees focused on improving treatment options for patients with lymphoma, including the American Society of Hematology, the American Society of Clinical Oncology, the Lymphoma Research Foundation (where she serves on the Scientific Advisory Board), ALLIANCE, and the Center for International Bone Marrow Transplant Registry (where she is Co-chair of the working group for Lymphoma). She was recently appointed as Vice-chair of the SWOG Lymphoma Committee. Through these organizations, Dr. Smith collaborates on research projects, provides physician education, and works on workshops and websites aimed at providing reliable information for patients and families affected by lymphoma. She is also on the Editorial Boards of the Journal of Clinical Oncology and Cancer. In addition, she has won several teaching awards at the University of Chicago, reflecting her commitment to training and education.

Back to Top
Jointly provided by:   and  
This activity is supported by unrestricted educational grants from Celgene Corporation and Takeda Oncology.
©2014 PCME